Stay updated on Cabozantinib and Nivolumab in Endometrial Cancer Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib and Nivolumab in Endometrial Cancer Clinical Trial page.

Latest updates to the Cabozantinib and Nivolumab in Endometrial Cancer Clinical Trial page
- CheckyesterdayChange DetectedRevision tag updated from v3.6.4 to v3.6.5 on the page, signaling a small update to the site. This change does not modify the study details or visible content.SummaryDifference0.0%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page revision tag was updated from v3.6.3 to v3.6.4, signaling a small update to the page version.SummaryDifference0.0%

- Check44 days agoChange DetectedThe page revision tag was updated from v3.6.0 to v3.6.3. This change reflects a newer build of the page content rather than a substantive modification.SummaryDifference0.0%

- Check58 days agoChange DetectedThe study page now indicates it is no longer recruiting participants, and new help sections (How to Read a Study Record, Common Questions, How to Join a Study) were added, while the Intervention/Treatment header was renamed from Intervention / Treatment and the revision label updated to v3.6.0.SummaryDifference0.3%

- Check65 days agoChange DetectedThe study plan now includes a new Sample Collection section added on 2026-06-02 as part of revision 3.5.5, superseding revision 3.5.4.SummaryDifference0.2%

- Check79 days agoChange DetectedGainesville site name was updated from University of Florida Health Science Center - Gainesville to UF Health Cancer Institute - Gainesville, and new entries for Diagnostic CAT Scan Service Type and Diagnostic CAT Scan were added to the imaging services.SummaryDifference0.3%

Stay in the know with updates to Cabozantinib and Nivolumab in Endometrial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib and Nivolumab in Endometrial Cancer Clinical Trial page.